Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021

Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021

BackgroundThe profiles of cardiovascular toxicity associated with angiogenesis inhibitors, including intravenous monoclonal antibodies (mAbs) and oral tyrosine kinase inhibitors (TKIs), targeting vascular endothelial growth factor (VEGF) remain poorly elucidated in real-world settings. This pharmaco...

Full description

Bibliographic Details
Main Authors: YanFeng Wang, Chanjuan Cui, Xiayang Ren, Xinran Dong, Wei Cui
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
cardiovascular toxicity
angiogenesis inhibitors
FAERS database
real-world study
disproportionality analysis
pharmacovigilance analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.988013/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.988013/full

Similar Items